Document Detail


Immunologic methods of purging in autologous stem cell transplantation.
MedLine Citation:
PMID:  10813528     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Malignant cells in the stem cell product have been shown to contribute to disease recurrence in patients who relapse after autologous transplantation. Immunologic methods of purging tumor cells from stem cell products focus on either removal of specific target cells or positive selection of HPC. mAb are the key component of many purging strategies and are employed both in vitro and in vivo. Cytotoxic cellular therapies are an emerging method of tumor cell eradication.
Authors:
L Berkahn
Related Documents :
16574858 - Stem cells and their niches.
20601088 - Stem cells in the spleen: therapeutic potential for sjogren's syndrome, type i diabetes...
12948308 - Ex vivo expansion of corneal limbal epithelial/stem cells for corneal surface reconstru...
12604368 - A glance into somatic stem cell biology: basic principles, new concepts, and clinical r...
21215748 - Flow cytometric mast cell-mediated cytotoxicity assay: a three-color flow cytometric ap...
1463458 - Erythroid expression and dnaasei-hypersensitive sites of the carbonic anhydrase 1 gene.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of hematotherapy & stem cell research     Volume:  9     ISSN:  1525-8165     ISO Abbreviation:  J. Hematother. Stem Cell Res.     Publication Date:  2000 Apr 
Date Detail:
Created Date:  2000-08-21     Completed Date:  2000-08-21     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  100892915     Medline TA:  J Hematother Stem Cell Res     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  147-59     Citation Subset:  IM    
Affiliation:
Section of Bone Marrow Transplant and Cell Therapy, Rush-Presbyterian St. Luke's Medical Center, Rush Medical College, Chicago, IL 60612, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Monoclonal / therapeutic use
Bone Marrow Purging / methods*
Cytotoxicity, Immunologic
Hematologic Neoplasms / therapy
Hematopoietic Stem Cell Transplantation / methods*
Humans
Killer Cells, Lymphokine-Activated / transplantation
Lymphoma / therapy
Recurrence / prevention & control
Transplantation, Autologous / methods
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6.
Next Document:  Osmometric and permeability characteristics of human placental/umbilical cord blood CD34+ cells and ...